Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)

While statistical non-inferiority was not met, exacerbation rates were low and symptom control/lung function were maintained in both groups. This first randomized, controlled switch trial in severe asthma suggests that participants with severe asthma on mepolizumab or benralizumab may safely switch to twice-yearly depemokimab.

Authors

Institutions

Publication Details

Journal
American Journal of Respiratory and Critical Care Medicine
Published
2026-02-04
DOI
https://doi.org/10.1093/ajrccm/aamag031
Citations
1
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
32.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)

John E. McGinniss, ANDRÉANNE CÔTÉ, P. Howarth, HIROYUKI NAGASE et al.
1 citations
American Journal of Respiratory and Critical Care Medicine
Asthma and respiratory diseases
32.84
article

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)

John E. McGinniss, ANDRÉANNE CÔTÉ, P. Howarth, HIROYUKI NAGASE, D Skowasch, Ian D. Pavord, Sherine O K, Daniel J Jackson, Gilles Devouassoux, NIMBLE Study Investigators, David J Jackson, Varsha Imber, Geoffrey Chupp, Michael E Wechsler
article en
1 citations

Abstract

While statistical non-inferiority was not met, exacerbation rates were low and symptom control/lung function were maintained in both groups. This first randomized, controlled switch trial in severe asthma suggests that participants with severe asthma on mepolizumab or benralizumab may safely switch to twice-yearly depemokimab.

American Journal of Respiratory and Critical Care Medicine
Université Claude Bernard Lyon 1 (FR), Rutgers, The State University of New Jersey (US), Guy's Hospital (GB), University of Wisconsin–Madison (US), Inserm (FR), King's College London (GB), University Hospital Bonn (DE), London International Development Centre (GB), Nuffield Orthopaedic Centre (GB), National Jewish Health (US), Yale University (US), University of Oxford (GB), Hôpital de la Croix-Rousse (FR), Hospices Civils de Lyon (FR), Glaxosmithkline (Finland) (FI), Institut universitaire de cardiologie et de pneumologie de Québec (CA), Virologie et Pathologies Humaines (FR), Office of International Affairs (US), Indian Institute of Management Bangalore (IN), Teikyo University (JP), University of Colorado Denver (US)
Openalex Percentile: Top 1%
Asthma and respiratory diseases
32.84
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE) — John E. McGinniss, ANDRÉANNE CÔTÉ, et al. · American Journal of Respiratory and Critical Care Medicine (2026) | TGRS Research Map | TGRS